Effects of Aminoglutethimide on Oestrogen Levels in Breast Cancer Patients
Author Information
Author(s): P.E. L0nning, D.C. Johannessen, T. Thorsen
Primary Institution: University of Bergen
Hypothesis
Does aminoglutethimide treatment reduce oestrone and oestrone sulphate production rates in breast cancer patients?
Conclusion
Aminoglutethimide treatment significantly reduces plasma levels and production rates of oestrone and oestrone sulphate in breast cancer patients.
Supporting Evidence
- Aminoglutethimide treatment reduced plasma oestrone levels by a mean of 46%.
- Oestrone sulphate levels were reduced by a mean of 71%.
- The production rate of oestrone was reduced by a mean of 31%.
- The clearance rate of oestrone increased by a mean of 30%.
- The fraction of oestrone sulphate converted into plasma oestrone was reduced by 52%.
Takeaway
This study shows that a drug called aminoglutethimide helps lower certain hormones in women with breast cancer, which might help treat their condition.
Methodology
Plasma levels, clearance, and production rates of oestrone and oestrone sulphate were measured in post-menopausal women receiving aminoglutethimide therapy.
Limitations
Small sample size and lack of control group.
Participant Demographics
Nine post-menopausal women with a mean age of 61.7 years.
Statistical Information
P-Value
p<0.05 and p<0.005 for different measures
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website